ABSTRACT
Background: REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike protein, and thus stops the progression of disease. We aim to evaluate the safety and efficacy of REGEN COV in patients presenting with Mild to moderate Covid 19 disease. Methodology: This is a retrospective observational study done in a tertiary hospital in South India. Patients admitted with RTPCR confirmed SARS COV 2 infection and within 10 days of symptoms onset were included in the trial. All patients received 1,200 mg each of casirivimab and imdevimab as a single intravenous infusion. All the patients were followed up for a period of 30 days with weekly telephonic consultation. Results: Between June 1 , 2021 and October 15 ,2021 , 30 patients got enrolled into the study and the mean age of patients was 60 years. The median duration from symptom onset to Regen Cov treatment was 5 days. Only 2 (10%) patients had adverse events and 83% of patients (25/30) had no symptoms after Regen Cov administration and 86% of patients (26/30) had no progression of clinical symptoms for up to 30 days after discharge. Conclusion: The monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) successfully prevented the progression of disease in 86% of patients presented with mild to moderate COVID 19 disease. Our study also underlined the safety of Regen Cov treatment with no major adverse event occurred in any of the patients.